Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma 10Breast Neoplasms 8Neutropenia 7Leukemia, Myeloid, Acute 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Febrile Neutropenia 4Leukemia, Monocytic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Retinoblastoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

pegylated granulocyte colony-stimulating factor 1Trastuzumab 1Omacor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breastcancer × pegylated granulocyte colony-stimulating factor × Clear all
NCT02944604 2019-01-18

The Efficacy and Safety of PEG-rhG-CSF(Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy

Peking University

Phase 4 Completed
240 enrolled
Breast

Breastcancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡